Pfizer and Moderna have developed new vaccines designed to target COVID's omicron mutation. Both manufacturers have asked the U.S. Food and Drug Administration to green-light their versions of the jab, which could be made available in September. In this week's episode, I speak with Dr. Christopher Doehring, vice president of medical affairs at Franciscan Health, to get his reaction to the news.